Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | MAT2A | P31153 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16666154 | 0.87 | NOTUM (0.46) | NOTUMHCRTR1ALDH1A1LMNAMEN1 | |
| SCHEMBL30048018 | 0.82 | KCNN4 (0.52) | HCRTR1ALDH1A1LMNAMEN1MAPT | |
| SCHEMBL17007197 | 0.82 | KCNN4 (0.52) | HCRTR1ALDH1A1LMNAMEN1MAPT | |
| SCHEMBL9955483 | 0.82 | HCRTR1 (0.46) | HCRTR1ALDH1A1LMNAMEN1MAPT | |
| SCHEMBL1339393 | 0.79 | ALDH1A1 (0.50) | MYCNR4A1HCRTR1ALDH1A1LMNA | |
| SCHEMBL17007296 | 0.79 | MYC (0.51) | MYCNR4A1NOTUMHCRTR1ALDH1A1 | |
| SCHEMBL16464646 | 0.78 | MEN1 (0.48) | HCRTR1ALDH1A1LMNAMEN1MAPT | |
| SCHEMBL1586432 | 0.78 | MYC (0.57) | MYCNR4A1NOTUMHCRTR1ALDH1A1 | |
| SCHEMBL30644067 | 0.78 | MYC (0.57) | MYCNR4A1NOTUMHCRTR1ALDH1A1 | |
| SCHEMBL30055522 | 0.77 | NOTUM (0.56) | NOTUMALDH1A1LMNAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| EP-3057957-B1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-9493432-B2 | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-3057957-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
| WO-2015055994-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015055994-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | CNR1, GABRR1, GRIN2A | MYC 2437/4885NR4A1 352/4885NOTUM 3800/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | MYC 3936/4885NR4A1 154/4885NOTUM 4545/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | MYC 3936/4885NR4A1 154/4885NOTUM 4545/4885 |
| US-20150232460-A1 | NOVEL COMPOUNDS | CNKSR1, RDX, RB1 | MYC 3928/4885NR4A1 446/4885NOTUM 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.